Integrated analysis of transcriptomic and metabolomic profiling reveal the p53 associated pathways underlying the response to ionizing radiation in HBE cells

Ruixue Huang1, Xiaodan Liu2, He Li1, Yao Zhou1,2 and Ping-Kun Zhou2,3*

Abstract
Background: Radiation damage to normal tissues is a serious concern. P53 is a well-known transcription factor which is closely associated with radiation-induced cell damage. Increasing evidence has indicated that regulation of metabolism by p53 represents a reviving mechanism vital to protect cell survival. We aimed to explore the interactions of radiation-induced transcripts with the cellular metabolism regulated by p53.

Methods: Human bronchial epithelial (HBE) cell line was used to knockout p53 using CRISPR/cas9. Transcriptomic analysis was conducted by microarray and metabolomic analysis was conducted by GC–MS. Integrative omics was performed using MetaboAnalyst.

Results: 326 mRNAs showed significantly altered expression in HBE p53-/ cells post-radiation, of which 269 were upregulated and 57 were downregulated. A total of 147 metabolites were altered, including 45 that increased and 102 that decreased. By integrated analysis of both omic data, we found that in response to radiation insult, nitrogen metabolism, glutathione metabolism, arachidonic acid metabolism, and glycolysis or gluconeogenesis may be dysregulated due to p53.

Conclusions: Our study provided a pilot comprehensive view of the metabolism regulated by p53 in response to radiation exposure. Detailed evaluation of these important p53-regulated metabolic pathways, including their roles in the response to radiation of cells, is essential to elucidate the molecular mechanisms of radiation-induced damage.

Introduction
Ionizing radiation (IR) is a term applied to any type of electromagnetic radiation, such as X-rays and y-rays, or particulate radiation, such as neutrons or alpha particles, containing sufficient energy to ionize atoms or molecules [1, 2]. The effects of radiation on cells can be characterized as a double-edged sword [3]. On one hand, IR has a therapeutic anticancer effect, acting to prevent cancer cell proliferation by inducing DNA double-strand break (DSB) damage; on the other hand, normal cells can be injured by IR [4]. For instance, a large radiation dose received over a short period of time will trigger the physiological response known as acute radiation syndrome (ARS) [5]. Furthermore, even low-dose IR exposure from diagnostic medical examinations, such as computed tomography (CT) scans, increases the overall cancer incidence by a factor of 1.54 (95% CI, 1.45–1.63; p<0.001) compared to the non-exposed population [6]. Previous evidence has indicated that the hematopoietic [7], gastrointestinal [8] and vascular systems [9] are...
most susceptible to IR-induced injury. In our laboratory, we noted that, after the initial treatment of cancer patients with 2 Gy radiation, multiple mRNAs changed significantly compared to their levels prior to radiation treatment, with most of the affected mRNAs, such as ALAS2 and HBG2, showing the effects of hematological toxicity [10]. In fact, while radiation injury generally depends on the dose, exposure duration, and type of radiation, as well as on the gender, age and health status of the exposed individual, the underlying molecular mechanisms are related to lipid, protein and DNA damage caused by direct ionization of target molecules, and to the effects of hydroxyl radicals formed via radiolysis of water molecules [11]. Regarding the cellular response to IR insult, DSB is the most common effect, resulting in either cell death or survival with mutations that may be repaired through non-homologous end-joining (NHEJ) and homologous recombination (HR) [12, 13].

The cancer suppressor p53 was first reported in 1981 [14], and defects in p53 are directly or indirectly associated with more than 50% of all human cancers, according to the International Cancer Genome Consortium (ICGC) [15]. The location of human p53 is on the short arm of chromosome 17 (17p13), and the protein size is 393 amino acids (~43 kDa). p53 contains a few structural domains, including the N-terminal domain, proline-rich domain, DNA-binding region, oligomerization domain and C-terminal domain. These domains can be visualized online (https://www.ncbi.nlm.nih.gov/gene/2768677).

Moreover, p53 is one of the most well-studied proteins in relation to radiation-induced DNA damage repair [16]. In the cellular response to IR, post-transcriptional modification of p53 at multiple sites triggers activation of biological functions by p53, including regulation of DNA damage repair, transient cell cycle arrest, apoptosis and terminal growth arrest [17, 18]. p53 executes these biological functions to repair IR-induced DNA damage through direct protein–protein interactions, such as the interaction with ATM, another key mediator of DSB repair [19], or indirectly through regulating the transcription of numerous p53-responsive genes [20, 21]. In recent years, increasing evidence has indicated that the accumulation of DNA damage is intimately linked to the onset of metabolic diseases, such as diabetes and obesity, and that the DNA damage response is involved in the regulation of metabolic homeostasis [22]. As the key regulator of DNA damage repair, p53 has been suggested to have an impact on systemic metabolism. Likewise, normal p53 activity is required for the physiological regulation of glucose metabolism. Yokoyama et al. indicated that upregulation of endothelial p53 led to metabolic abnormalities [23]. Meanwhile, Franklin et al. reported that p53 promotes nucleotide biosynthesis in response to DNA damage by repressing expression of the rate-limiting enzyme for glycolysis [24]. Hence, DNA damage-induced p53 activation plays critical roles in metabolic diseases, such as obesity and diabetes, suggesting that fine-tuning of the DNA damage response is essential for preventing and treating metabolic diseases [22]. Clarifying the regulatory role of p53 in metabolism would provide new insights into IR-induced DNA damage repair, radiotherapy-related resistance and DNA damage-induced dysregulation of metabolism, and thus promote more precise cancer therapy through identification of preventative and therapeutic targets for clinical application.

With the continual development of scientific technologies, transcriptomic and metabolomic analyses have been increasingly applied for uncovering molecular mechanisms and novel biomarkers based on high-throughput data [25, 26]. Transcriptomics refers to research on the complete set of RNA transcripts produced by the genome under specific circumstances, and is carried out using high-throughput methods including microarray analysis [27, 28]. Metabolomics is defined as analysis of the variations in endogenous metabolites in response to stressors such as radiation exposure in biological systems, including cells and tissues [29]. Metabolomic methods have been applied not only to discover biomarkers, but also to improve therapeutic outcomes through identification of metabolites and analysis of the variations therein [30]. We hypothesized that p53-dependent radiation injury is related to alterations of both the transcriptome and metabolome. To explore the interactions of radiation-induced transcripts with the cellular metabolism regulated by p53, we performed integrated transcriptomic and metabolomic analysis of the p53 knockout human bronchial epithelial (HBE) cell line (HBE p53-/-). Our data show that multiple mRNAs and metabolites are significantly altered after IR exposure in HBE p53-/- cells compared to HBE p53-wildtype (HBE p53-wt) cells. Moreover, “joint pathway analysis” showed that arachidonic acid metabolism, nitrogen metabolism, glutathione metabolism, glycolysis and gluconeogenesis may be controlled by p53 during the response to IR-induced damage.

Methods and materials

Cell line, CRISPR/cas9 method
The HBE cell line, purchased from the American Type Culture Collection, was cultured in bronchial epithelial cell growth medium containing all SingleQuots supplements (Cambrex Corporation, East Rutherford, NJ, USA) except hydrocortisone. The cells were incubated at 37°C in 5% carbon dioxide, passaged at 90% confluence, and cultured in 6- or 12-well plates. HBE cells were sent to Syngentech Ltd. (Beijing, China) for p53 knockout using the CRISPR/cas9 method. In brief, the main steps for
p53 knockout using CRISPR/cas9 were as follows. First, three sgRNAs were designed: pHS-ACR-LW601(5′-CGG ACGATATTGAAACATGG-3′), pHS-ACR-LW602(5′-ACCAGCAGCTCTACACCGG-3′), and pHS-ACR-LW603(5′-GTGCTGTAGCTTGTAGA-3′). These three primers were inserted into the sgRNA backbone to construct the lentivirus plasmids. Then, the lentivirus plasmids were transfected with HEK 293FT cells using EpFect™ Transfection Reagent (Syngentech). After 48 h, the liquid containing transfected lentivirus plasmids was collected for determination of viral titer. Sequence detection was used to identify the plasmids. We used the packaged p53 gene-silencing lentivirus to infect the target cell line with the optimal multiplicity of infection (MOI) value, and obtained the p53 knockout HBE cell line through Puro resistance screening.

Transcriptome detection through microarray analysis and validation with quantitative real-time polymerase chain reaction (qRT-PCR)

HBE cells in two groups, the HBE p53-wt group and HEB p53-/- group, were harvested 24 h after exposure to 4 Gy radiation and sent to OE Biotech Ltd. (Shanghai, China) for microarray transcriptome analysis. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed into cDNA using the ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, Japan) according to the manufacturers’ instructions. The GeneChip Fluidics Station 450, GeneChip Hybridization Oven 645, and GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA, USA) were used to detect mRNA changes in the HBE p53-wt and HBE p53-/- groups after exposure to 4 Gy radiation. In our laboratory, we previously conducted integrated analysis of lncRNA-mRNA co-expression networks in α lung bronchial epithelial cells with -particle-induced carcinogenesis [31]. Fold changes greater than 2 and p-values less than 0.05 were considered to represent significant changes in mRNAs. qRT-PCR was carried out in our laboratory using the Super Real PreMix Plus (SYBR Green) kit (Tiangen Biotech, Beijing, China) on the CFX96TM Real-Time system (Bio-Rad Laboratories, Hercules, CA, USA), to validate the changes and trends observed in the microarray analysis. The comparative Ct (2−ΔΔCt) method was used to calculate relative fold differences in mRNA expression between HBE p53-/- and HBE p53-wt cells [32, 33]. mRNA expression levels were compared using the two-tailed Student’s t-test. Differences were considered significant at p < 0.01 after false discovery rate correction for multiple tests.

Gene Ontology (GO) analysis of the changes in mRNA was performed, focusing on molecular functions, cellular components and biological processes (http://geneontology.org/). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was applied to the collection of manually drawn pathway maps representing known molecular interactions, reactions and relationships for metabolism, genetic information processing, environmental information processing, cellular processes, organismal systems, human diseases and drug development (https://www.kegg.jp/kegg/pathway.html).

Western blot analysis

Protein extraction and western blot assays were conducted according to the manufacturers’ instructions, as described previously [34, 35]. Antibodies against p53 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA) and Abcam (Cambridge, UK). Images were captured and assessed using the ChemiDoc XRS + system (Bio-Rad Laboratories). Protein expression was quantified using Image Lab software (Bio-Rad Laboratories). At least three independent replicates were analyzed for each sample.

Metabolomic analysis via gas chromatography-mass spectrometry (GC–MS)

Metabolomic analysis involved the extraction of metabolites and GC–MS analysis. Briefly, HBE cells were divided into HBE p53-wt and HBE p53-/- groups. The cells were harvested 24 h after exposure to 4 Gy radiation. Metabolites were extracted according to the following steps: addition of 80 μL BSTFA (including 1% TMCs) as the derivative reagent and 20 μl n-hexane, followed by addition of 11 internal standards (C8/C9/C10/C12/C14/ C16, 0.8 mg/ml; C18/C20/C22/C24/C26, 0.4 mg/ml, all in chloroform) at 10 μl each, 2-min vortex mixing, and a final reaction at 70 °C for 60 min. These samples were used for the GC–MS analysis. The chromatographic conditions were as follows: Db-5 ms capillary column (30 m × 0.25 mm × 0.25 μm; J&W Scientific, Folsom, CA, USA), carrier gas of high-purity helium (purity of at least 99.999%), flow rate of 1.0 ml/min, and sample inlet temperature of 260 °C. The injection volume was 1 μL, and the solvent was added after 5 min. The temperature program was as follows: initial column chamber temperature of 60 °C, rising to 125 °C at a rate of 8 °C/min and then to 210 °C at 5 °C/min, followed by heating to 270 °C at 10 °C/min and maintenance at 305 °C for 5 min after increasing the rate of increase to 20 °C/min. The mass spectrometry conditions were as follows: electron-bombardment ion source, ion source temperature of 230 °C, quadrupole temperature of 150 °C, and electron energy of 70 eV. The scanning mode used was full scan mode (SCAN), with a scanning range of m/z 50–500.
Bioinformatic analysis
The bioinformatic analysis involved identification of significantly altered mRNAs and metabolites, 24 h after exposure to 4 Gy radiation through a combination of multi- and single-dimension analyses. To illustrate the relationships among samples, and their metabolite expression differences, hierarchical clustering was performed and variable importance in projection (VIP) values were calculated. Pearson correlation analysis was used to detect relationships among significantly altered metabolites according to changes in biological status. Metabolic pathway enrichment data were obtained through KEGG analysis of various metabolites (http://www.kegg.jp/) [36]. A $p$-value < 0.05 was considered significant; --log $p$-values were also calculated [37].

Finally, integrated transcriptomic and metabolomic analyses were conducted using the MetaboAnalyst (https://www.metaboanalyst.ca/MetaboAnalyst/home.xhtml). The joint pathway analysis module was selected. mRNA official gene symbols and KEGG IDs of metabolites were uploaded for topology analysis, to assess the potential importance of individual molecules (i.e., nodes) based on their positions within the network. The network metrics of degree centrality and betweenness centrality were used to determine the number of links that connect to a node, and the number of shortest paths from all nodes to all other nodes that pass through a given node, respectively. Closeness centrality was used to measure the overall distance from a given node to all other nodes [38–40].

Statistics
Statistical analysis was performed using SPSS 22.0 (IBM Corp., Armonk, NY, USA), GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, USA) and R 3.2.5 (Development Core Team, Vienna, Austria) software. Data are generally provided as means ± standard deviations or counts (percentages). Differences between two groups were determined using the paired $t$-test, Wilcoxon signed rank sum test or $t$-test. A two-tailed $p$-value < 0.05 was considered statistically significant.

Results
Loss of p53 significantly alters mRNA expression
Western blotting was used to determine the p53 knock-out efficiency (Fig. 1a) in CRISPR/Cas9-mediated p53-knockout HBE cells (p53-/-). To ascertain whether p53 deficiency affected mRNA expression post-radiation, we compared mRNA expression levels between the p53-/- HBE and p53-wt HBE cells. We conducted this analysis 24 h after 4 Gy radiation exposure, because human lung branchial epithelial cells exhibit 4 Gy-induced radiation injury (i.e., significant DNA damage) at this timepoint, based on our previous studies [31, 33, 41–43]. According to the transcriptomic data, 326 mRNAs showed significantly altered expression in HBE p53-/- cells post-radiation, of which 269 were upregulated and 57 were downregulated (Fig. 1b). Table 1 lists the top 20 differentially expressed mRNAs in p53-wt compared to p53-KO HBE cells after 4 Gy radiation. DEFA6, SLC3A1, and SCN1A were the three most strongly upregulated mRNAs, with fold changes of approximately 78, 20 and 19, respectively. C8orf86, LOC112268013, and MATK were the three most strongly downregulated mRNAs, with fold changes of 0.13, 0.216 and 0.217, respectively. The data show that p53 can regulate numerous mRNAs, indicating the critical role of p53 in the response to radiation. However, the affected mRNAs could be either directly or indirectly regulated by p53, as p53 is a transcriptional factor that may regulate other transcriptional factors in response to radiation.

Next, we constructed a heatmap of dysregulated (i.e., upregulated or downregulated) mRNAs within the HBE p53-wt and HBE p53-/- groups (Fig. 1c). Figure 1d shows a volcano plot of the two groups: the number of upregulated mRNAs was greater than the number of downregulated mRNAs. GO analysis of the 30 mRNAs showing the largest changes was conducted to identify their possible biological functions; as shown in Fig. 2, those mRNAs are mainly enriched in neuron projection extension, neuron projection guidance, and the semaphorin–plexin signaling pathway involved in neuron projection guidance. Regarding molecular functions, the top 30 mRNAs were enriched primarily in semaphorin receptor activity, cytokine binding and serine-type endopeptidase activity. Regarding cellular components, these mRNAs are mainly related to the plasma membrane, extracellular space and semaphorin receptor complex. We then conducted KEGG prediction analysis (Fig. 3a), which revealed that the signal transduction, signaling molecules and interaction, and immune system pathways are the top 3 pathways predicted in HBE p53-/- cells post-radiation, with 30–40 mRNAs enriched in each, consistent with the results of GO analysis.

We subjected the five mRNAs showing the largest changes to qRT-PCR analysis, to validate the microarray data. As shown in Fig. 3b, the expression levels of DEFA6, SLC3A1, SCN1A, ENTHD1 and RSPH6A were upregulated after 4 Gy radiation exposure, while those of C8orf86, LOC112268013, MATK, TMEM56-RWDD3 and SCT were downregulated, consistent with the microarray results.

Loss of p53 significantly changes metabolites
To explore the p53-dependent changes in cellular metabolites after radiation insult, HBE cells were divided into HBE p53-wt and HBE p53-/- groups, as
described previously. Cells were harvested 24 h after 4 Gy radiation exposure, and their metabolite profiles were constructed based on the GC–MS data. A total of 35 metabolites changed significantly in HBE p53-/- cells compared to p53-wt cells ($p < 0.05$). A total of 147 metabolites were altered, including 45 that increased and 102 that decreased. Table 2 lists the top 35 most altered metabolites, including 5 that increased and 30 that decreased. Among them, erythronic acid lactone, hydroxylamine, oleamide, 1,3-diphosphoglycerol and O-phosphoethanolamine were upregulated, while 4-hydroxymandelic acid, erythronic acid, epsilon-caprolactam, allothreonine and metharbital were down-regulated, in HBE p53-/- cells post-radiation. The dysregulated metabolites belong to multiple metabolic classes, including lactones, phenols, organo-oxygen compounds, carboxylic acids (and their derivatives purine nucleosides, and fatty acyls), indicating that p53 deficiency leads to dysregulation of multiple metabolic classes, which may result in changes in related metabolic
pathways. The data show that p53 plays a critical role in regulating radiation-induced metabolic changes. To identify the metabolites most closely associated with the p53 deficiency, VIP analysis was performed and the results are shown in Table 2. Using 1.00 as the VIP cutoff score, 35 metabolites were identified as being potentially closely associated with p53 deficiency.

To further understand the alterations in p53 knockout-related metabolites post-radiation, we used a heatmap and volcano plot to visually represent upregulated and downregulated metabolites. As shown in Fig. 4a, compared to the p53-wt group, metabolites were significantly downregulated in the p53 knockout group post-radiation. The volcano plot also shows that more metabolites were downregulated than upregulated (Fig. 4b). To investigate the interactions among these altered metabolites, we conducted Pearson correlation analysis. As shown in Fig. 4c, the expression level of erythronic acid lactone was positively correlated with those of hydroxylamine and oleamide, while 1,3-diphosphoglycerol expression was positively correlated with that of O-phosphoethanolamine. On the other hand, phytosphingosine expression was negatively correlated with that of erythronic acid lactone. The correlation analysis showed that metabolites may exhibit interactions during radiation-induced cell injury. The metabolomic data confirmed that p53 has a wide range of regulatory effects on intracellular metabolism in response to radiation. We also performed KEGG analysis, which indicated that the nitrogen metabolism, sphingolipid metabolism, glycolysis/gluconeogenesis and glycine, serine and threonine metabolism pathways changed significantly based on the 35 most altered metabolites (Fig. 5a). These data suggest that p53 may regulate metabolites via these metabolic pathways.

### Table 1 Top 20 differential expressed genes/mRNAs in the p53-wt vs. p53-KO HBE cells post 4 Gy radiation

| Upregulated mRNA | Downregulated mRNA |
|------------------|--------------------|
| Gene-ID | Fold change | log2 (fold) | p value | Gene-ID | Fold change | log2 (fold) | p value |
|.DEFA6 | 78.33913 | 6.291661 | 1.38E−11 | C8orf86 | 0.130736 | 1.000000 | 0.009803 |
| SLC3A1 | 20.16322 | 4.333661 | 0.003823 | LOCI12268013 | 0.216001 | 2.210899 | 0.00971 |
| SCN1A | 19.79819 | 4.307297 | 0.004904 | MATK | 0.217973 | 2.19778 | 0.006171 |
| ENTDH1 | 16.45192 | 4.040184 | 0.013362 | TMEM56-RWDD3 | 0.252377 | 1.98635 | 0.039409 |
| RSPH6A | 13.827 | 3.789416 | 0.001236 | SCT | 0.256374 | 1.96368 | 0.023869 |
| CHRNA6 | 12.5158 | 3.645679 | 0.045863 | P2RY4 | 0.267326 | 1.90333 | 0.014581 |
| SLC25A6 | 10.65712 | 3.413746 | 0.011851 | LCN2 | 0.303939 | 1.71815 | 5.85E−15 |
| FAM163B | 9.699409 | 3.277897 | 7.21E−07 | SPRK2 | 0.306724 | 1.70499 | 3.68E−13 |
| TASR3 | 9.304103 | 3.217867 | 0.000423 | SLC26A4 | 0.316586 | 1.65933 | 4.28E−25 |
| RXYF4 | 8.349756 | 3.061734 | 0.005335 | POTEI | 0.318255 | 1.65174 | 0.02425 |
| MANSC4 | 7.434827 | 2.894299 | 0.011991 | STK32A | 0.325094 | 1.62107 | 1.93E−17 |
| GPR84 | 7.172444 | 2.842465 | 0.003795 | GPR93 | 0.326626 | 1.61429 | 2.71E−05 |
| U2AF1 | 6.906392 | 2.787932 | 0.00111 | CD69 | 0.336596 | 1.57091 | 0.003493 |
| FAM19A3 | 6.628252 | 2.728628 | 0.026354 | LPAR6 | 0.338796 | 1.56151 | 1.84E−07 |
| CESSA | 6.442318 | 2.68758 | 0.010618 | NTS7 | 0.333169 | 1.50157 | 2.36E−06 |
| KCN2 | 6.295374 | 2.654292 | 0.026678 | FLNC | 0.355741 | 1.4911 | 1.45E−15 |
| SNCB | 6.047667 | 2.596379 | 0.044324 | INFD | 0.360171 | 1.47325 | 0.021089 |
| MAP2K6 | 5.47041 | 2.451649 | 0.000226 | GZMB | 0.378744 | 1.40071 | 4.97E−18 |
| LHFL1 | 5.383789 | 2.428622 | 0.000288 | LOC102724219 | 0.389122 | 1.3617 | 0.032583 |
| DEFA6 | 78.33913 | 6.291661 | 1.38E−11 | LGALS7B | 0.380833 | 1.35907 | 0.02712 |

*p < 0.05 represents significantly changed*

Integrated transcriptomic and metabolomic analyses of p53-dependent metabolic pathways

Multiple-omic analysis is a comprehensive modality that can greatly increase the validity of results [44]. Most importantly, integrating metabolic and transcriptomic data can uncover significantly perturbed pathways at both the metabolic and transcriptional levels, thereby providing a basis for further investigation of the underlying molecular mechanisms [45]. Thus, we used MetaboAnalyst 4.0 to conduct joint pathway analysis of transcriptomic and metabolomic data [40, 46]. The mRNA enrichment and metabolic pathway analyses revealed 37 significantly altered pathways, at both the metabolic and mRNA expression levels, in HBE p53-/- cells, where these pathways are involved in nitrogen metabolism, glutathione metabolism, glycolysis or gluconeogenesis, and arachidonic acid metabolism,
among other processes (Table 3). Figure 5b shows the altered pathways, including the metabolic pathways of interest. Four metabolic pathways, i.e., nitrogen metabolism, glutathione metabolism, arachidonic acid metabolism, and glycolysis or gluconeogenesis, had p-values < 0.05 and impact coefficients > 0.2, indicating that, in response to radiation insult, these pathways may be dysregulated due to p53. These four metabolic pathways showed significant differences in HBE p53-/- cell mRNA expression after radiation exposure (highlighted in red in Fig. 5c, b). As shown in Fig. 5c, in the arachidonic acid metabolism pathway, the expression levels of GGT1, PLA2G, PTGS and GPX6 were altered in HBE p53-/- cells post-radiation. Figure 5d shows that, in the nitrogen metabolism pathway, CA5B was altered in HBE p53-/- cells post-radiation, while Fig. 6a shows that in the glutathione metabolism pathway, ALDOA, ACSS2 and ALDH3A1 were altered in HBE p53-/- cells; finally, Fig. 6b shows that in the glycolysis or gluconeogenesis pathway, GGT6 and GPX6 were affected in HBE p53-/- cells. These data indicate that the changes seen in mRNA expression levels may be related to p53-dependent alteration of metabolic pathways (Additional file 1: Fig. S1).
To validate the transcriptomic and metabolomic results, HBE cells were divided into four groups: p53-wt, p53-wt treated with 4 Gy radiation (p53-wt –IR), p53-/-, and p53-/- treated with 4 Gy radiation (p53-/- IR). Cells were harvested 24 h after 4 Gy radiation, and GGT1, PLA2G, PTGS, GPX6, ALDOA, ACSS2, ALDH3A1, GGT6 expression levels were determined using qRT-PCR. As shown in Fig. 5g, compared to the untreated p53-wt group, the GGT1, PLA2G, PTGS, GPX6, ALDOA, ACSS2, ALDH3A1, GGT6 expression levels were significantly reduced in p53-wt after treatment with 4 Gy radiation. On the other hand, compared to untreated p53-/- cells, GGT1, PLA2G, PTGS, GPX6, ALDOA, ACSS2, ALDH3A1, GGT6 expression levels were significantly elevated in p53-/- cells after treatment with 4 Gy radiation (Fig. 6c). We also performed study on the effects of p53 knockout on the radiation-associated epithelial to mesenchymal (EMT) in HBE cells. The data is shown at Additional file 2: Fig. S2, illustrating the p53 knockout would promote development of radiation-associated epithelial to mesenchymal.

These findings are thus consistent with the transcriptomic and metabolomic results, providing further evidence that the involvement of these genes in dysregulation of radiation-related metabolic pathways may be p53-dependent, and also supporting the importance of p53 in the regulation of radiation-induced cell damage.

**Discussion**

Since p53 was first identified, numerous studies have indicated that p53 plays essential roles in biological processes [47]. Our laboratory has focused on p53 regulation of radiation-induced injury over the past decade, and this study was performed to assess the potential interactions of mRNA and metabolites regulated by p53 during the cellular response to radiation. In this study, 326 mRNAs changed significantly in p53-/- cells in response to 4 Gy radiation exposure, including 269 mRNAs that increased and 102 that decreased. Integrated transcriptomic and metabolomic analysis indicated that GGT1, PLA2G, PTGS, GPX6, ALDOA, ACSS2, ALDH3A1, GGT6, which are involved in nitrogen metabolism, glutathione metabolism, glycolysis or gluconeogenesis, and arachidonic acid metabolism, are regulated by p53. Our study provides deep insight.
into p53-mediated mRNA and metabolic regulation in response to radiation insult, and identifies key mRNAs and metabolites, as potential targets of p53, for future studies of the underlying molecular mechanisms.

As a key cancer suppressor, p53 has been intensively studied in terms of its role in regulating cellular processes such as autophagy, cell cycle arrest and senescence, when cells are subjected to stress [48]. In particular, p53 plays a crucial role in the cellular response to radiation. In previous studies, the p53-mediated cellular response to radiation, which includes apoptosis and cell cycle arrest, appeared unnecessary for its cancer-suppressing function; moreover, compared to p53 knockout mice, cancer was not

| Metabolites                        | VIP*   | log2 (FC) | p-value | Class                        | Sub class                                      |
|-----------------------------------|--------|-----------|---------|------------------------------|-----------------------------------------------|
| Erythronic acid lactone           | 1.06922| 0.6158    | 6.9E-05 | Lactones                     | Organoheterocyclic compounds                  |
| Hydroxylamine                     | 1.34941| 0.19798   | 0.04045 | Homogeneous other non-metal compounds | Homogeneous non-metal compounds                |
| 4-hydroxymandelic acid            | 1.36889| -0.6996   | 0.00142 | Phenols                      | Benzenoids                                     |
| Erythronic acid                   | 1.42277| -1.7093   | 0.00929 | Organoxygen compounds        | Organic oxygen compounds                        |
| Epsilon-caprolactam               | 1.34602| -0.7127   | 0.00061 | Lactams                      | Organoheterocyclic compounds                  |
| Allothreonine                     | 1.46924| -0.5049   | 0.00792 | Carboxylic acids and derivatives | Organic acids and derivatives                  |
| Metharbital                       | 1.41033| -1.0301   | 0.00381 | Diazines                     | Organoheterocyclic compounds                  |
| Nicotinic acid                    | 1.42734| -0.5283   | 0.00083 | Pyridines and derivatives    | Organoheterocyclic compounds                  |
| 3,3-dimethyl-1-hydroxy-cyclohexene| 1.009  | -1.3095   | 0.00151 | –                            | –                                             |
| Cyanoline                         | 1.40793| -0.7455   | 9.4E-05 | –                            | –                                             |
| 2,4-diaminobutyric acid           | 1.4873 | -0.793    | 0.03173 | Carboxylic acids and derivatives | Organic acids and derivatives                  |
| Isocitric acid                    | 1.43121| -1.3229   | 0.01103 | Carboxylic acids and derivatives | Organic acids and derivatives                  |
| Alpha-tocopherol                  | 1.47328| -1.0729   | 0.00435 | Prenol lipids                | Lipids and lipid-like molecules               |
| Arbutin                           | 1.06715| -1.2865   | 0.00725 | Organoxygen compounds        | Organic oxygen compounds                        |
| 5-hydroxymethyl-2-furoic acid     | 1.38372| -2.0063   | 0.00456 | Furans                       | Organoheterocyclic compounds                  |
| Alloxaonic acid                   | 1.15251| -2.265    | 0.0279  | –                            | –                                             |
| 3-hydroxybenzoic acid             | 1.4286 | -1.47     | 0.00704 | Benzenes and substituted derivatives | Benzenoids                                     |
| 4-hydroxyphenylacetic acid        | 1.34886| -0.7195   | 0.01778 | Phenol esters                | Benzenoids                                     |
| Succinylacetone                   | 1.00743| 3.6389    | 0.01924 | Keto acids and derivatives   | Organic acids and derivatives                  |
| Chlorogenic acid                  | 1.01029| -2.1308   | 0.00706 | Organoxygen compounds        | Organic oxygen compounds                        |
| Tocopherol acetate                | 1.3993 | -1.8671   | 0.01908 | Prenol lipids                | Lipids and lipid-like molecules               |
| Pseudo uridine                    | 1.24524| -0.4121   | 0.03491 | Nucleoside and nucleotide analogues | Nucleosides, nucleotides, and analogues |
| Epicatechin                       | 1.37918| -0.9262   | 0.01609 | Flavonoids                   | Phenylpropanoids and polyketides              |
| O-phosphoethanolamine             | 1.37653| 0.87116   | 0.04621 | Organic phosphoric acids and derivatives | Organic acids and derivatives                  |
| Azelaic acid                      | 1.13179| -1.3106   | 0.00278 | Fatty Acyls                  | Lipids and lipid-like molecules               |
| Beta-glutamic acid                | 1.22441| -0.4523   | 0.03566 | –                            | –                                             |
| Lactobionic acid                  | 1.34112| -1.0772   | 0.01633 | –                            | –                                             |
| Arsenate                          | 1.03192| -1.9182   | 0.00398 | Miscellaneous mixed metal/non-metals | Mixed metal/non-metal compounds |
| Palatinol                         | 1.27221| -0.7068   | 0.0263  | –                            | –                                             |
| L-allothreonine                   | 1.38117| -0.6869   | 0.04396 | Purine nucleosides           | Nucleosides, nucleotides, and analogues       |
| Oleamide                          | 1.02286| 0.2853    | 0.01158 | Fatty Acyls                  | Lipids and lipid-like molecules               |
| 1,3-diphosphoglycerol             | 1.12954| 1.4098    | 0.0293  | –                            | –                                             |
| D-erythro-sphingosine             | 1.24636| -0.5613   | 0.02118 | Organonitrogen compounds     | Organic nitrogen compounds                     |
| Phytosphingosine                  | 1.11899| -0.6993   | 0.0023  | Organonitrogen compounds     | Organic nitrogen compounds                     |

A positive value indicates up regulation and a negative value indicates down regulation

* VIP variable important in projection. The larger the VIP, the greater the contribution of this variable to the grouping; log2 (FC): the ratio of the average expression amount of metabolites in the two groups of samples
Recently, increasing evidence has shown that cancer does not occur in mice with p53 mutations, which nonetheless retain p53 activity for regulation of energy metabolism; this suggests that p53 activities in the context of metabolic regulation may be critical for suppression of tumorigenesis [51]. Numerous cancer studies of the metabolic pathways regulated by p53 have been conducted recently [52–54]. As noted by Gomes et al. in their review article, p53 activation is involved in the complex process of reprogramming cancer glucose metabolism [55]. However, no studies have used multiple-omic techniques to provide a global perspective on p53-dependent metabolic regulation of the response to radiation stress. Thus, the goal of this study was to reveal the transcriptomic and metabolomic alterations that occur in response to radiation insult.

Several studies of radiation-induced transcriptome changes have been published in recent years. Stankevicius et al. reported that the response of human colorectal carcinoma (DLD1) cells to a single exposure to 2 or 10 Gy induced differential expression of 1575 genes, and KEGG analysis showed that the p53 pathway was the most significantly altered in those cells [56]. Moreno-Villanueva et al. investigated gene expression in individual human T lymphocytes 3 h after ex vivo exposure to 2 Gy γ-rays, and identified a group of TP53-responsive genes that are involved in the interferon-γ pathway [57]. Molt-4-LXSN cells expressing wild-type p53, and p53-deficient Molt-4-E6 cells, were γ-irradiated; 14 h later, multiple genes were found to be dysregulated in p53-deficient Molt-4-E6 cells, including PMAIP1, CDKN1A and FAS, which are involved in the p53 pathway [58]. These transcriptomic studies indicate that p53 plays a key regulatory role in

Fig. 4 Bioinformatic analysis of metabolomics. a A heatmap was used to visually represent upregulated and downregulated metabolites. b A volcano was used to visually represent upregulated and downregulated metabolites. c The interactions among altered metabolites were analyzed by pearson correlation analysis.
Fig. 5  Integrated transcriptomic and metabolomic analyses of p53-dependent metabolic pathways.  

a KEgg analysis of significantly altered metabolites.  
b The mRNA enrichment and metabolic pathway analyses was based on joint pathways using MetaboAnalyst 4.0.  
c The arachidonic acid metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout.  
d The nitrogen metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout.
IR-induced damage. Our data are consistent with previous research showing that the expression levels of multiple mRNAs were significantly altered due to changes in p53 status after radiation exposure. As a cancer suppressor, p53 deficiency commonly leads to tumorigenesis. Thus, although the p53-/- HBE cell model used in this study may not be optimal in all circumstances, it could be used to investigate the p53-mediated metabolic regulation associated with radiation stress.

Integration of transcriptomic and metabolomic data may yield greater insight into radiation-induced damage than either approach alone. In their review, Volkova et al. noted that multiple-omics approaches are useful for radioecological research [59]. Moreover, Sproull et al. stated that -omics techniques to assess individuals exposed to radiation injury, such as those affected by radiological or nuclear events, are necessary [60].

In our study, the genes altered in response to radiation (GGT1, PLA2G, PTGS, GPX6, ALDOA, ACSS2, ALDH3A1, GGT6) were involved in nitrogen metabolism, glutathione metabolism, glycolysis or gluconeogenesis and arachidonic acid metabolism, and were regulated by p53. Nitrogen metabolism has been reported to regulate global gene expression in human

---

| Pathway name                                  | Match status | P           | Impact     |
|-----------------------------------------------|--------------|-------------|------------|
| Fructose and mannose metabolism              | 1/40         | 0.37213     | 0.25641    |
| Tyrosine metabolism                           | 3/88         | 0.077606    | 0.22989    |
| Pyrimidine metabolism                         | 2/99         | 0.31535     | 0.22449    |
| Nitrogen metabolism                           | 2/10         | 0.0054      | 0.22222    |
| Glutathione metabolism                        | 3/56         | 0.024996    | 0.21818    |
| Glycolysis or Gluconeogenesis                 | 3/61         | 0.03124     | 0.2        |
| Phenylalanine metabolism                      | 1/21         | 0.21603     | 0.2        |
| Pyruvate metabolism                           | 1/45         | 0.40794     | 0.18182    |
| Arachidonic acid metabolism                   | 5/81         | 0.001919    | 0.175      |
| Propanoate metabolism                         | 1/48         | 0.42847     | 0.17021    |
| Purine metabolism                             | 2/166        | 0.57811     | 0.1697     |
| Thiamine metabolism                           | 1/14         | 0.14958     | 0.15385    |
| Biotin metabolism                             | 1/21         | 0.21603     | 0.15       |
| Taurine and hypotaurine metabolism            | 1/16         | 0.1691      | 0.13333    |
| Retinol metabolism                            | 1/47         | 0.42171     | 0.13043    |
| Linoleic acid metabolism                      | 1/17         | 0.17869     | 0.125      |
| Drug metabolism-cytochrome P450               | 2/98         | 0.31104     | 0.1134     |
| Ether lipid metabolism                        | 1/39         | 0.36472     | 0.10526    |
| Nicotinate and nicotinamide metabolism        | 2/42         | 0.082504    | 0.097561   |
| Alpha-Linolenic acid metabolism               | 1/22         | 0.2251      | 0.095238   |
| Glycine, serine and threonine metabolism      | 2/68         | 0.18248     | 0.089552   |
| Primary bile acid biosynthesis                | 2/92         | 0.28513     | 0.087912   |
| Pentose phosphate pathway                     | 1/47         | 0.42171     | 0.086957   |
| Glycerocephospholipid metabolism              | 2/86         | 0.25918     | 0.070588   |
| Histidine metabolism                          | 1/32         | 0.31045     | 0.064516   |
| Fatty acid degradation                        | 2/102        | 0.32824     | 0.059406   |
| Starch and sucrose metabolism                 | 1/43         | 0.39386     | 0.047619   |
| Fatty acid biosynthesis                       | 1/129        | 0.78338     | 0.046875   |
| beta-Alanine metabolism                       | 1/44         | 0.40094     | 0.046512   |
| Cysteine and methionine metabolism            | 1/71         | 0.56461     | 0.042857   |
| Glyoxylate and dicarboxylate metabolism       | 1/56         | 0.47992     | 0.036364   |
| Sphingolipid metabolism                      | 1/58         | 0.49207     | 0.035088   |
| Folate biosynthesis                           | 1/61         | 0.50978     | 0.033333   |
| Metabolism of xenobiotics by cytochrome P450  | 2/145        | 0.50302     | 0.027778   |
| Steroid hormone biosynthesis                  | 1/199        | 0.90892     | 0.020202   |
Fig. 6 Integrated transcriptomic and metabolomic analyses of p53-dependent metabolic pathways. a The glutathione metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout. b The glycolysis or gluconeogenes metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout. c GGT1, PLA2G, PTGS, GPX6, ALDOA, ACS52, ALDH3A1, GGT6 expression levels were determined using qRT-PCR in HBE cells of p53-wt, p53-wt treated with 4 Gy radiation (p53-wt –IR), p53-/-, and p53-/- treated with 4 Gy radiation (p53-/- IR), respectively. The data are presented as the means ± SDs from three independent experiments; * p < 0.05 between different groups.
fibroblasts in response to γ-rays, by activating the p53 signaling pathway [61]. In glutathione metabolism, glutamine provides additional carbon and nitrogen for cell growth [62], thereby driving glutathione synthesis, and contributes to radiation sensitivity in lung cancer cell lines [62]. Glycolysis and gluconeogenesis have been extremely well characterized in many studies; during glycolysis, the glucose molecule is divided into two pyruvate molecules, which leads to the generation of lactate in cancer cells. Metabolic pathways based on glycolysis include the pentose phosphate and hexosamine biosynthetic pathways [63]. p53 also plays a mediating role in glycolysis. A previous report indicated that p53 induces TIGAR (a TP53-induced glycolysis and apoptosis regulator) to decrease PFK1 (6-phosphofructokinase 1) activity and reduce the glycolytic rate [64]. Zhang et al. showed that p53 negatively regulates glycolysis under hypoxic conditions in cancer cells, through targeting of Ras-related associated with diabetes (RRAD) [65]. Arachidonic acid is metabolized to epoxyeicosatrienoic acid through the p53-mediated apoptotic pathway [66]. Although these metabolic pathways have previously been reported to show associations with p53, few studies have focused on radiation-induced damage to cellular metabolic pathways under conditions of p53 deficiency. The present study highlights the most important metabolic pathways regulated by p53 in response to radiation. Furthermore, our results indicate that exposure to radiation under p53 deficiency conditions can result in significant dysregulation of both the transcriptome and metabolome.

Despite using multiple-omics to observe global biological changes following exposure to radiation, and providing important data showing the involvement of p53-regulated mRNA and metabolites in the radiation-induced damage response, this study had limitations. First, only one cell line was used; studies using multiple cell lines could validate the results. Second, we did not investigate whether the observed transcriptomic and metabolomic alterations under p53 deficiency conditions are dose- or time-dependent. Third, we did not perform functional analyses to uncover the molecular mechanisms underlying the observed changes.

Conclusions
Our study provided a pilot comprehensive view of the metabolism regulated by p53 in response to radiation exposure. Detailed evaluation of these important p53-regulated metabolic pathways, including their roles in the response to radiation of cells, is essential to elucidate the molecular mechanisms of radiation-induced damage.
medical countermeasures, and biomarker development to predict clinical outcome. Health Phys. 2019;116:433.

6. Hong JY, Han K, Jung JH, Kim JS. Association of exposure to diagnostic low-dose ionizing radiation with risk of cancer among youths in South Korea. JAMA Netw Open. 2019;2:e1910584.

7. MacVittie TJ, Farese AM, Jackson W 3rd. The hematopoietic syndrome of the acute radiation syndrome in rhesus macaques: a systematic review of the lethal dose response relationship. Health Phys. 2015;109:342–66.

8. MacVittie TJ, Farese AM, Parker GA, Jackson W 3rd, Booth C, Tudor GL, et al. The gastrointestinal subsyndrome of the acute radiation syndrome in rhesus macaques: a systematic review of the lethal dose-response relationship with and without medical management. Health Phys. 2019;116:305–38.

9. Venkatesulu BP, Mahadevan LS, Aliri ML, Yang X, Bodd MH, Singh PK, et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Trans Sci. 2018;3:563–72.

10. Nie YH, Liu XD, Huang R, Xie D, Yin WJ, Guan H, et al. Analysis of mRNA expression patterns in peripheral blood cells of 3 patients with cancer after the first fraction of 2 Gy irradiation: an integrated case report and systematic review. Dose Response. 2019;17:1559325819833474.

11. Fukao T, Kaneko H, Birrell G, Gatei M, Tashita H, Yoshida T, et al. ATM is upregulated during the mitogenic response in peripheral blood mononuclear cells. Blood. 1999;94:1998–2006.

12. Frankenberg-Schwager M. Review of repair kinetics for DNA damage induced in eukaryotic cells in vitro by ionizing radiation. Radiat Oncol. 1989;14:307–20.

13. Li M, You L, Xue J, Lu Y. Ionizing radiation-induced cellular senescence in normal, non-transformed cells and the involved dna damage response: a mini review. Front Pharmacol. 2018;9:522.

14. Crawford L, Pien DC, Gurney EG, Goodfellow P, Taylor-Papadimitriou J. Detection of a common feature in several human tumor cell lines—a 53,000-dalton protein. Proc Natl Acad Sci USA. 1981;78:741–5.

15. Hellweg CE, Spitta LF, Henschammer B, Diegeler S, Baumstark-Khan C. Transcription factors in the cellular response to charged particle exposure. Front Oncol. 2016;6:61.

16. Lee CL, Castle KD, Moding EJ, Blum JM, Williams N, Luo L, et al. Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma. Nat Commun. 2015;6:8477.

17. Kotobash I, Merrifield M, Kovalchuk O. Fractionated exposure to low doses of ionizing radiation results in accumulation of DNA damage in mouse spleen tissue and activation of apoptosis in a p53/Atm-independent manner. Int J Radiat Biol. 2017;93:148–55.

18. Guo L, Liew HP, Camus S, Coh AM, Chee LL, Lunny DP, et al. Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Oncogene. 2013;32:4009–16.

19. Rybinska-Spaeder I, Reynolds TL, Zhou J, Prakash M, Jefferson T, Huo DL, et al. SSBP1 is limiting for NHEJ repair in ATM-deficient model systems that are subjected to oncogenic stress or radiation. Mol Cancer Res. 2013;11:1223–34.

20. Wildel M, Lakal A, Krzywona A, Poleszczuk J, Fujarewicz K, Rzeszowska-Wolny J. The different radiation response and radiation-induced bystander effects in colorectal carcinoma cells differing in p53 status. Mutat Res. 2015;778:61–70.

21. Mitzuyama R, Andris R, Scott A, Wang YW, Murray D. Ionizing radiation-induced responses in human cells with differing TP53 status. Int J Mol Sci. 2013;14:22409–35.

22. Shimizu I, Yoshida Y, Suda M, Minamoto T. DNA damage response and metabolic disease. Cell Metab. 2014;20:967–77.

23. Yokoyama M, Okada S, Nakagomi A, Moriya J, Shimizu I, Nojima A, et al. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. Cell Rep. 2014;7:1601–703.

24. Franklin DA, He Y, Leslie PL, Tikunov AP, Fenger N, Macdonald JM, et al. Mechanism of caspatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxcollet. Vitr. 2015;30:117–27.

25. Wilmes A, Bielow C, Ranninger C, Bellworn P, Aschauer L, Lomnicz A, et al. Mechanism of caspatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxcollet. Vitr. 2015;30:117–27.

26. Lu X, Hu B, Shao L, Tian Y, Jin T, Jin Y, et al. Integrated analysis of transcriptomics and metabolomics profiles in aflatoxin B1-induced hepatotoxicity in rat. Food Chem Toxicol. 2013;55:444–55.

27. Alfaq M, Alghamdi SS, Migdadi HH, Khattar MA, Mirza SB, et al. Legume genomics: and transcriptomics. from classic breeding to modern technologies. Saudi J Biol Sci. 2020;27:543–55.

28. Ricard-Blum S, Miele AE. Omic approaches to decipher the molecular mechanisms of fibrosis, and design new anti-fibrotic strategies. Seminars in cell & developmental biology. Cambridge: Academic Press; 2019.

29. Li E, He X, Jia W, Li H. Novel applications of metabolomics in personalized medicine: a mini-review. Molecules. 2017;22:1173.

30. Zhang F, Zhang Y, Zhao W, Deng W, Wang Z, Yang C, et al. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review. Oncotarget. 2017;8:35460–72.

31. Liu XD, Xie D, Wang YL, Guan H, Huang RX, Zhou PK. Integrated analysis of lncRNA-mRNA coexpression networks in the alpha-particle induced carcinogenesis of human branchial epithelial cells. Int J Radiat Biol. 2019;95:144–55.

32. Zhou Y, He L, Liu XD, Guan H, Li Y, Huang RX, et al. Integrated analysis of IncRNA and mRNAs transcriptome reveals new regulators of ubiquitinopathy and the immune response in silica-induced pulmonary fibrosis. Biomed Res Int. 2019;2019:630565.

33. Mo LJ, Song M, Huang QH, Zhou PK. Integrated analysis of transcription factors in the cellular response to charged particle exposure. Front Oncol. 2016;6:61.

34. Qin J, Ning H, Zhou Y, Hu Y, Huang B, Wu Y, et al. LncRNA Uc. 173 is a key molecule for the regulation of lead-induced renal tubular epithelial cell apoptosis. Biomed Pharmacother. 2018;100:101–7.

35. Qin J, Ning H, Zhou Y, Hu Y, Yang L, Huang R. LncRNA MIR31HG overexpression serves as poor prognostic biomarker and promotes cells proliferation in lung adenocarcinoma. Biomed Pharmacother. 2018;99:363–8.

36. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KGEG: new perspectives on genomics, patheways, diseases and drugs. Nucleic Acids Res. 2017;45:D353–61.

37. Wang M, Wang L, Pu L, Li K, Feng T, Zheng P, et al. LncRNAs related key pathways and genes in ischemic stroke by weighted gene co-expression network analysis (WGCNA). Genomics. 2020;112:2302.

38. Chong J, Wishart DS, Xia J. Using metaboanalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Prot Bioinform. 2018;68:e86.

39. Chong J, Yamamoto M, Xia J. MetaboAnalyst R 2.0: from raw spectra to biological insights. Metabolites. 2019;9:57.

40. Chong J, Soufan O, Li C, Carusas I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018;46:W486–94.

41. Liu Z, Liang X, Li X, Liu X, Zhu M, Gu Y, et al. lncRNA-21 functions in ionizing radiation-induced epithelium-to-mesenchymal transition (EMT) by downregulating PTEN. Toxicol Res. 2019;8:328–40.

42. Chen S, Liu R, Wang Q, Qi Z, Hu Y, Zhou P, et al. Mir-34 s negatively regulate homologous recombination through targeting RAD51. Arch Biochem Biophys. 2019;666:73–82.

43. Huang R, Zhou P. Double-edged effects of noncoding RNAs in responses to environmental genotoxic insults: perspectives with regards to molecule-ecology network. Environ Pollut. 2019;247:64–71.

44. Bjornson M, Balcke GU, Xiao Y, de Souza A, Wang JJ, Zhabinskaya D, et al. Integrated omics analyses of retrograde signaling mutant delineate intermolecule-ecology network. Environ Pollut. 2019;247:64–71.

45. Ren S, Shao Y, Zhao X, Hong CS, Wang F, Lu X, et al. Integration of metabolomics and transcriptomics reveals major metabolic pathways and potential biomarker involved in prostate cancer. Mol Cell Proteomics. 2019;18:154–63.

46. Cambiaghi A, Ferrario M, Masseroli M. Analysis of metabolomic data: tools, current strategies and future challenges for omics data integration. Brief Bioinform. 2017;18:498–510.

47. Deepa, Pundir S, Pundir CS. Detection of tumor suppressor protein p53 with special emphasis on biosensors: a review. Anal Biochem. 2020;588:113473.

48. Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65–72.
49. Valente LJ, Gray DH, Michalak EM, Pinon-Hoffbauer J, Egle A, Scott CL, et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013;3:1339–45.

50. Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008;15:1019–29.

51. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269–83.

52. Kaymak I, Maier CR, Schmitz W, Campbell AD, Dankworth B, Ade CP, et al. Mevalonate pathway provides ubiquinone to maintain pyrimidine synthesis and survival in p53-deficient cancer cells exposed to metabolic stress. Cancer Res. 2019;80:189.

53. Matsuura K, Canfield K, Feng W, Kurokawa M. Metabolic regulation of apoptosis in cancer. Int Rev Cell Mol Biol. 2016;327:43–87.

54. Aylon Y, Oren M. The Hippo pathway, p53 and cholesterol. Cell Cycle. 2016;15:2248–55.

55. Gomes AS, Ramos H, Soares J, Saraiva L. p53 and glucose metabolism: an orchestra to be directed in cancer therapy. Pharmacol Res. 2018;131:75–86.

56. Stankevicius V, Vatauskas G, Rynkeviciene R, Venius J, Pasukoniene V, Aleknavicius E, et al. Microenvironment and dose-delivery-dependent response after exposure to ionizing radiation in human colorectal cancer cell lines. Radiat Res. 2017;188:291–302.

57. Moreno-Villanueva M, Zhang Y, Feiveson A, Mistretta B, Pan Y, Chatterjee S, et al. Single-cell RNA-sequencing identifies activation of TP53 and STAT1 pathways in human T lymphocyte subpopulations in response to ex vivo radiation exposure. Intern J Mol Sci. 2019;20:2316.

58. Hage-Sleiman R, Bahmad H, Kobeissy F, Dhaibo G. Genomic alterations during p53-dependent apoptosis induced by gamma-irradiation of Molt-4 leukemia cells. PLoS ONE. 2017;12:e0190221.

59. Volkova PY, Geras’kin SA. ‘Omic’ technologies as a helpful tool in radioecological research. J Environ Radioact. 2018;189:156–67.

60. Sproull MT, Campahausen KA, Koblentz GD. Biodosimetry: a future tool for medical management of radiological emergencies. Health Secur. 2017;15:599–610.

61. Sokolov MV, Panyutin IG, Neumann RD. Whole-genome gene expression profiling reveals the major role of nitric oxide in mediating the cellular transcriptional response to ionizing radiation in normal human fibroblasts. Genomics. 2012;100:277–81.

62. Sappington DR, Siegel ER, Hiatt G, Desai A, Penney RB, Jamshidi-Parsian A, et al. Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines. Biochem Biophys Acta. 2016;1860:836–43.

63. Vanhove K, Graulus GJ, Mesotten L, Thomeer M, Derveaux E, Noben JP, et al. The metabolic landscape of lung cancer: new insights in a disturbed glucose metabolism. Front Oncol. 2019;9:1215.

64. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–20.

65. Zhang C, Liu J, Wu R, Liang Y, Lin M, Liu J, et al. Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget. 2014;5:5535–46.

66. Hye Khan MA, Fish B, Wahl G, Sharma A, Falck JR, Paudyal MP, et al. Epoxycisatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clin Sci. 2016;130:587–99.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.